A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)
Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, an...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/2/224 |
| _version_ | 1797617901370343424 |
|---|---|
| author | Hassen Mohammed Dan Duy Pham-Tran Zi Yi Michelle Yeoh Bing Wang Mark McMillan Prabha H. Andraweera Helen S. Marshall |
| author_facet | Hassen Mohammed Dan Duy Pham-Tran Zi Yi Michelle Yeoh Bing Wang Mark McMillan Prabha H. Andraweera Helen S. Marshall |
| author_sort | Hassen Mohammed |
| collection | DOAJ |
| description | Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose. |
| first_indexed | 2024-03-11T08:02:34Z |
| format | Article |
| id | doaj.art-2ca7420f5d0a49ea9cfcde516b100b2b |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T08:02:34Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-2ca7420f5d0a49ea9cfcde516b100b2b2023-11-16T23:41:28ZengMDPI AGVaccines2076-393X2023-01-0111222410.3390/vaccines11020224A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529)Hassen Mohammed0Dan Duy Pham-Tran1Zi Yi Michelle Yeoh2Bing Wang3Mark McMillan4Prabha H. Andraweera5Helen S. Marshall6Vaccinology and Immunology Research Trials Unit, Women’s and Children’s Health Network, Adelaide, SA 5006, AustraliaRobinson Research Institute and Adelaide Medical School, the University of Adelaide, Adelaide, SA 5006, AustraliaRobinson Research Institute and Adelaide Medical School, the University of Adelaide, Adelaide, SA 5006, AustraliaVaccinology and Immunology Research Trials Unit, Women’s and Children’s Health Network, Adelaide, SA 5006, AustraliaVaccinology and Immunology Research Trials Unit, Women’s and Children’s Health Network, Adelaide, SA 5006, AustraliaVaccinology and Immunology Research Trials Unit, Women’s and Children’s Health Network, Adelaide, SA 5006, AustraliaVaccinology and Immunology Research Trials Unit, Women’s and Children’s Health Network, Adelaide, SA 5006, AustraliaReal-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.1.1.529) is limited. This systematic review aimed to investigate the real-world effectiveness and durability of protection conferred by primary course and booster vaccines against confirmed Omicron infection, and severe outcomes. We systematically searched literature up to 1 August 2022. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled vaccine effectiveness (VE). Overall, 28 studies were included representing 11 million individuals. The pooled VE against Omicron infection was 20.4% (95%CI: 12.1–28.7%) and 23.4% (95%CI: 13.5–33.3%) against symptomatic infection with variation based on vaccine type and age groups. VE sharply declined from 28.1% (95%CI: 19.1–37.1%) at three months to 3.9% (95%CI: −24.8–32.7%) at six months. Similar trends were observed for symptomatic Omicron infection. A booster dose restored protection against Omicron infection up to 51.1% (95%CI: 43.8–58.3%) and 57.3% (95%CI: 54.0–60.5%) against symptomatic infection within three months; however, this waned to 32.8% (95%CI: 16.8–48.7%) within six months. VE against severe Omicron infection following the primary course was 63.6% (95%CI: 57.5–69.7%) at three months, decreased to 49% (95%CI: 35.7–63.4%) within six months, and increased to 86% after the first or second booster dose.https://www.mdpi.com/2076-393X/11/2/224COVID-19Omicronvaccine effectivenessCOVID-19 vaccinesbooster vaccination |
| spellingShingle | Hassen Mohammed Dan Duy Pham-Tran Zi Yi Michelle Yeoh Bing Wang Mark McMillan Prabha H. Andraweera Helen S. Marshall A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) Vaccines COVID-19 Omicron vaccine effectiveness COVID-19 vaccines booster vaccination |
| title | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
| title_full | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
| title_fullStr | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
| title_full_unstemmed | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
| title_short | A Systematic Review and Meta-Analysis on the Real-World Effectiveness of COVID-19 Vaccines against Infection, Symptomatic and Severe COVID-19 Disease Caused by the Omicron Variant (B.1.1.529) |
| title_sort | systematic review and meta analysis on the real world effectiveness of covid 19 vaccines against infection symptomatic and severe covid 19 disease caused by the omicron variant b 1 1 529 |
| topic | COVID-19 Omicron vaccine effectiveness COVID-19 vaccines booster vaccination |
| url | https://www.mdpi.com/2076-393X/11/2/224 |
| work_keys_str_mv | AT hassenmohammed asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT danduyphamtran asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT ziyimichelleyeoh asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT bingwang asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT markmcmillan asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT prabhahandraweera asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT helensmarshall asystematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT hassenmohammed systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT danduyphamtran systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT ziyimichelleyeoh systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT bingwang systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT markmcmillan systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT prabhahandraweera systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 AT helensmarshall systematicreviewandmetaanalysisontherealworldeffectivenessofcovid19vaccinesagainstinfectionsymptomaticandseverecovid19diseasecausedbytheomicronvariantb11529 |